UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL				
OMB Number:	3235-0287			
Estimated average burden				
hours per response.	0.5			

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

(Print or Type Respon

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person * Kelly Paul Edward		Issuer Name and Ticker or Trading Symbol RELMADA THERAPEUTICS, INC. [RLMD] 3. Date of Earliest Transaction (Month/Day/Year) 07/29/2019					5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X_ Director									
(Last) (First) (Middle) C/O RELMADA THERAPEUTICS, INC., 880 THIRD AVENUE, 12TH FLOOR (Street)																
			4. If Amendment, Date Original Filed(Month/Day/Year)													
NEW YORK,, NY 10022 (City) (State) (Zip)			Tabla I - Nan-Darivativa Securities Acqu													
(Instr. 3) Date		2. Transaction Date (Month/Day/Year	Execut any	A. Deemed recution Date, if		ransacti	saction 4. Securities Acqui (A) or Disposed of		quired of (D)	5. Amount of So Owned Followi Transaction(s)		ecurities Beneficially		wnership of orm:	Nature f Indirect eneficial	
				(Mont)	h/Day/Yea		ode	V A	mount (A) o	Price	or Indirect (I)		Indirect (In	vnership astr. 4)		
Reminder:							ir	n this f	orm are not	require	d to re	espond u		on contained form display		74 (9-02)
Temmder.							ir	n this f	orm are not	require	d to re	espond u				74 (9-02)
1. Title of	Price of	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	(e.g., p) 4. Transac Code	5. Nu Deriv Secur Acqu	mber o ative ities ired (A	equired ts, option f 6. D Exp: (Mo	n this for currer I, Dispo	orm are not notly valid OM sed of, or Ben nvertible securcisable and Date	required IB continue reficially rities) 7. Title of Und Securi	Owne e and A	espond u mber. d Amount	8. Price of	9. Number of Derivative Securities Beneficially	10. Ownership Form of Derivative	11. Natur of Indired Beneficia Ownersh
1. Title of Derivative Security	Conversion or Exercise	Date	3A. Deemed Execution Date, if any	(e.g., p) 4. Transac Code	5. Nu Deriv Secur Acqu	mber of ative ities fired (A sposed . 3, 4,	equired ts, option f 6. D Exp: (Mo	n this for currer d, Disport ons, con oate Exertization I	orm are not notly valid OM sed of, or Ben nvertible securcisable and Date	required IB continue reficially rities) 7. Title of Und Securi	Owne e and Aderlying	espond u mber. d Amount	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	10. Ownership Form of Derivative Security: Direct (D) or Indirect	11. Natur
1. Title of Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	(e.g., p) 4. Transac Code	5. Nution Deriv Securior Di (D) (Instr	mber o ative ities ired (A sposed	cquired ts, option f 6. D Exp (Mo) of Date Exer	n this for currer 1, Disposions, cor Date Executation I onth/Day	orm are not ntly valid ON sed of, or Bei nvertible securicisable and Date //Year)	required IB continue reficially rities) 7. Title of Und Securi	Owne e and Aderlying ities 3 and 4	espond u mber. d Amount	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported	10. Ownership Form of Derivative Security: Direct (D) or Indirect	11. Natur of Indired Beneficia Ownersh

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Kelly Paul Edward C/O RELMADA THERAPEUTICS, INC. 880 THIRD AVENUE, 12TH FLOOR NEW YORK,, NY 10022	X					

Signatures

/s/ Paul E. Kelly	07/30/2019
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Pursuant to the terms of the company's 2014 Stock Option and Equity Incentive Plan, 6.25% of the options shall vest each quarter from the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.